Friday Morning, February 22, 2019
Moderator: William M. Mendenhall, MD
8:00-8:05  Welcome  Paul Okunieff, MD
8:05-9:00  Risk-adapted radiation therapy of early breast cancer: Learning when to say “No”  David Wazer, MD
9:00-9:20  Misuse of QOL evaluations: Reification, adaptation and the U-shaped curve  Robert Amdur, MD
9:20-9:30  Radiotherapy for head and neck paragangliomas  William Mendenhall, MD
9:30-9:50  Stereotactic ablative radiotherapy for prostate cancer oligometastases  Roi Dagan, MD, MS
9:50-10:10  Outcomes after proton therapy for skull-base chordoma  Adam Holtzman, MD
10:10-10:25  Break
10:25-10:45  NRG Oncology – RTOG 1203 update  Anamaria Yeung, MD
10:45-11:05  The science of oligometastasis in the era of immunotherapy  Paul Okunieff, MD
11:05-11:25  RadTox: Using cfDNA for prediction of radiation toxicity in prostate cancer patients  Natalie Lockney, MD
11:25-11:45  Concurrent chemotherapy and hypofractionated proton therapy for stage II-III non-small cell lung cancer  Bradford Hoppe, MD, MPH
11:45-1:00  Lunch Break

Friday Afternoon, February 22, 2019
Moderator: Randal H. Henderson, MD, MBA
1:00-1:20  Motion study of prostate RT with GoldAnchor™ and SpaceOAR™  Soon Huh, PhD
1:20-1:40  History of marijuana use and prostate cancer  R. Charles Nichols, MD
1:40-2:00  Proton therapy for adult craniopharyngiomas  Michael Rutenberg, MD, PhD
2:00-2:20  Proton therapy for orbital and pelvic rhabdomyosarcoma  Daniel Indelicato, MD
2:20-2:40  Proton therapy for pediatric nasopharyngeal carcinoma  Haruka Uezono, MD
2:40-2:55  Radiation dose-effect for the optic nerves and chiasm in pediatric brain tumor patients  James Bates, MD
2:55-3:10  Proton therapy for skull base and cranium Ewing sarcoma  Shivam Kharod, MD
3:10-3:25  Break
3:25-3:45  Patterns of failure in parameningeal alveolar rhabdomyosarcoma  Julie A. Bradley, MD
3:45-4:05  Determining the value of information of proton therapy for women with non-metastatic breast cancer  Raymond Mailhot Vega, MD
4:05-4:20  Breast cancer survivors’ unmet needs after completion of radiation therapy  Michelle Pembroke, BSN, RN, OCN
4:20-4:40  Assessing the impact of dose calculation algorithms on IMPT for breast cancer  Xiaoying Liang, PhD
4:40-5:00  COMPPARE Update  Nancy Mendenhall, MD
5:00  Meeting Adjourns
Saturday Morning, February 23, 2019
Moderator: Robert A. Zlotecki, MD, PhD

8:00-9:00  Risk of cardiac morbidity and mortality after radiation for breast cancer: Overblown or under-appreciated?  
David Wazer, MD

9:00-9:15  Disparities in patterns of care among insured and uninsured patients with anal-rectal cancer  
Catherine Mercado, MD

9:15-9:30  A SEER cervix cancer analysis  
Sommer Nurkic, MD

9:30-9:45  Evaluating the concept that late recurrence is common after radiotherapy for benign meningioma  
Lillie O’steen, MD

9:45-10:00  Non-clinical and elective opportunities in radiation oncology residency training  
Akash Parekh, MD

10:00-10:15  Radiotherapy for squamous cell carcinoma of the soft palate  
Cooper Rapp, MD

10:15-10:30  Break

10:30-10:45  Radiotherapy for differentiated thyroid cancer  
E. Charles Fortune, MD

10:45-11:00  Radiotherapy for solitary plasmacytoma  
Jayden Curry, MS2

11:00-11:20  Emergency Department Presentation of Radiotherapy Patients  
Laura Towery, MS2, and David Tyson, MS2

11:20-11:35  RadTox Confounders: Identifying clinical conditions that increase plasma circulating cfDNA levels  
Jennifer Li, MS2

11:35-12:00  Awards Ceremony

12:00  Adjourn